Appendix Cancer and PMP Patient Registry and Natural History Study
Official title: The ACPMP Research Foundation Appendix Cancer/PMP Patient Registry
Run by Appendix Cancer Pseudomyxoma Peritonei Research Foundation · NCT07769346 · Data updated 2026-11-12
This global, patient-powered registry tests how appendix cancer and pseudomyxoma peritonei progress over time by collecting real-world data from patients and caregivers.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 10000 (estimated) |
| Sponsor | Appendix Cancer Pseudomyxoma Peritonei Research Foundation Academic / other |
| Locations | 1 site (Springfield, Pennsylvania) |
| Status | Recruiting |
| Started | February 2, 2026 |
| Main results expected | February 1, 2030 |
| Study ends | February 1, 2030 |
| Registry record updated | August 17, 2026 |
| Trial ID | NCT07769346 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with appendix cancer or PMP and who can provide informed consent or have a legally authorized representative to enter information.
✕Probably not a fit
Patients not meeting inclusion criteria or unable to provide informed consent may not benefit from the registry.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational registry collects longitudinal information from individuals affected by appendix cancer and PMP to understand disease characteristics, clinical course, treatment patterns, and outcomes. Data are gathered via online surveys, with optional uploads of pathology reports, genomic sequencing, and other medical documents. The study emphasizes regulatory-grade data quality under IRB oversight and supports future research and clinical trial development. Participation is open to patients or their authorized representatives who can provide informed consent and contribute retrospective or prospective information.
Why it matters
Potential benefit: If successful, the registry could improve disease understanding and inform standards of care and future clinical trials for appendix cancer and PMP.
How similar studies have gone: Other rare-disease registries and natural history studies have shown value in informing research directions and trial design, though this specific patient-powered registry is relatively novel for appendix cancer/PMP.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of appendix cancer. * Meets the study inclusion criteria for participation. * Participant or, when applicable, a legally authorized representative (LAR) is able to provide informed consent and enter information into the Registry. * A designated representative may provide retrospective information for an individual who died from appendix cancer, as permitted by the study protocol. Exclusion Criteria: * Individuals who do not meet the study inclusion criteria. * Individuals for whom required informed consent cannot be obtained.
Where it's running
-
Acpmp
Springfield, Pennsylvania, United States Recruiting
Study contacts
- Principal investigator: Deborah Shelton — Acpmp
- Study coordinator: Margaret Najarian
- Email: patientregistry@acpmp.org
- Phone: (833) 227-6773
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Metformin in PMP from appendiceal mucinous neoplasms
This pilot study tests whether metformin is feasible to use in adults with pseudomyxoma peritonei caused by appendiceal mucinous tumors who have recurrent or unresected disease.
-
Pseudovax: a vaccine for people with pseudomyxoma peritonei
This trial will test whether the Pseudovax peptide vaccine with GM‑CSF plus the PD‑1 drug tislelizumab can boost anti‑tumor immunity in adults with GNAS‑mutated pseudomyxoma peritonei.
-
One versus three HIPEC cycles after cytoreductive surgery for pseudomyxoma peritonei
This study will see if giving three HIPEC sessions instead of one after cytoreductive surgery helps people with pseudomyxoma peritonei live longer, delay disease progression, and keep a better quality of life.
-
Neoadjuvant treatment for patients with advanced Pseudomyxoma peritonei
This study is testing a new combination of medications to see if it can help patients with advanced Pseudomyxoma peritonei have better surgery results.
-
Imaging method for digestive system cancer using targeted PET scans
This study is testing a new type of PET scan to see if it can better help doctors find and diagnose cancers in the digestive system.
-
Comparing low-dose and high-dose chemotherapy for treating Pseudomyxoma Peritonei
This study is testing if a lower dose of chemotherapy given for a shorter time can work just as well as a higher dose for treating Pseudomyxoma Peritonei.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.